These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 11336056)
1. Upper gastrointestinal toxicity of rofecoxib and naproxen. Delgado Fernández M; Zambrana García JL; Diez García F N Engl J Med; 2001 May; 344(18):1398; author reply 1398-9. PubMed ID: 11336056 [No Abstract] [Full Text] [Related]
2. [Coxib instead of NSAID plus gastric acid inhibitor. Protection for the small intestine]. MMW Fortschr Med; 2004 Mar; 146(13):61. PubMed ID: 15219139 [No Abstract] [Full Text] [Related]
3. [Prevention of ulcer lesions under non-steroid antirheumatic agents. For each patient the appropriate stomach protection]. MMW Fortschr Med; 2004 May; 146(22):48. PubMed ID: 15373113 [No Abstract] [Full Text] [Related]
4. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment. Chan FK; Graham DY Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194 [TBL] [Abstract][Full Text] [Related]
5. Upper gastrointestinal toxicity of rofecoxib and naproxen. Gupta S N Engl J Med; 2001 May; 344(18):1398; author reply 1398-9. PubMed ID: 11336057 [No Abstract] [Full Text] [Related]
7. Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs. Wolfe MM Int J Clin Pract Suppl; 2003 Apr; (135):32-7. PubMed ID: 12723745 [TBL] [Abstract][Full Text] [Related]
13. Upper gastrointestinal complications related to non-steroidal anti-inflammatory drugs--what have we achieved so far? Wong VW; Leong RW; Chan FK Dig Liver Dis; 2004 Jan; 36(1):1-3. PubMed ID: 14971808 [No Abstract] [Full Text] [Related]
14. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912 [TBL] [Abstract][Full Text] [Related]
15. The management of upper gastrointestinal problems in patients taking NSAIDs. Prichard P Aust Fam Physician; 1991 Dec; 20(12):1739-41. PubMed ID: 1687198 [TBL] [Abstract][Full Text] [Related]
16. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Goldstein JL; Huang B; Amer F; Christopoulos NG Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480 [TBL] [Abstract][Full Text] [Related]
17. A patient with high risk of gastrointestinal bleeding requiring nonsteroidal anti-inflammatory drugs. Wilcox CM; Ladabaum U Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1090-3. PubMed ID: 16890026 [No Abstract] [Full Text] [Related]
18. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rahme E; Nedjar H Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138 [TBL] [Abstract][Full Text] [Related]
20. Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. Choi HK; Seeger JD; Kuntz KM Am J Med; 2004 May; 116(9):621-9. PubMed ID: 15093759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]